Few population-based studies have examined the descriptive epidemiology and seroprevalence of herpes simplex virus (HSV) infection. Some of the obstacles to gathering such information are the difficulty in obtaining population-based serum samples, the lack of medical and sexual history data of patient populations in which seroprevalence studies have been done, and the lack of a highly specific serologic test to differentiate between antibody to type I and type 2 HSV.
The recent development of type-specific serologic techniques has made possible more precise estimates of the extent of infection with herpes simplex type 2 (HSV-2). ' Between 1978 and 1980 , the prevalence of antibody to HSV-2 in the white residential population of Toronto, Canada, was estimated as 15.5% by a precise method for distinguishing between HSV -1 and HSV-2.
2 Using another new, more specific serologic method, preiiminary data from a U.S. national survey showed a prevalence of HSV -2 antibody of 16.4% amttng non-institutionalized civilian residents. 3 We report the first nationally representative data from Costa Rica on the prevalence of antibody to types 1 and 2 herpes simplex virus (using the same specific serolog.ic test used in the U.S. national survey) and the first populationbased study that examines demographic characteristics and medical and sexual histories in relation to the presence of HSV -2 antibody.
MA TERlALS AND METHODS
Compared with women in developed nations, Costa Rican women have a higher incidence of cervical cancer and a lower incidence of.breast cancer. 0 In 1984-1985, the Costa Rican Demographic Association in collaboration with the Centers for Disease Control (CDC), the Costa Rican Social Security Administration. the Ministry ofHealth, and Family Health International conducted a case-control study of these 2 cancers. Details of the study design and population have been reported elsewhere. [6] [7] [8] [9] [10] The current analysis is restricted to the population-based control series from that study and describes seroprevalence ofHS V antibody rather than incidence. The control sample consisted of a cross-section of women in the 25-59 year age group. They were selected in a nationally representative cluster sample survey based on the June 1984 census. Sample points in sparsely settled areas. representing 5% of the population, were excluded. Of the 938 women eligible as controls, 92.8% were interviewed in their homes by trained female interviewers using a standard questionnaire modified from the CDC Cancer 224 and Steroid Hormone Study. 11 Interviews lasted an averageof40 min and focused on the women's reproductive. medical. and sexual histories.
After receiving informed consent. laboratory technicians obtained serum specimens from 88% of the interviewed control women. Sera were analyzed for ami bodies to HSV -1 and HSV -2 (at the Division of Pediatric Infectious Diseases, Emory University) with a type-specific glycoprotein antigen, 1 and for antibody to Chlamydia trachomatis'~ (at the Chlamydia Laboratory, San Francisco General Hospital). The MHA-TP and RPR tests for syphilis were performed at the STD Laboratory, Center for Infectious Diseases, CDC.
Because the social and demographic characteristics of women who had a serum specimen drawn did not differ from those of women who did not, 13 the analysis was restricted to those women for whom a serum specimen was obtained. Sampling fractions used in selecting controls varied by age group in order to match the age distribution of the cancer cases for the original case control study. In order tb obtain population estimates of seroprevalence, the results for the current analysis were age-weighted by the inverse of the sampling fractions to compensate for the over-sampling of women in certain age groups.
14 Demographic and reproductive history variables were cross-tabulated with age and with the number of lifetime sexual partners to characterize seropositivity. Cells with <25 women are not presented. Since the population survey was based on a multi-stage, duster sample methodology, confidence intervals were calculated using a Taylor series approximation of the variance.14
RE.StiLTS
Fewer than I o/o of the women reported a history of oral herpes lesions. The prevalence of HSV-1 antibody was 97.1% with minimal differences by population subgroups. When analyzed by age, region, or education level, >90% of the women in each subgroup were seropositive for HSV-1.
Very few women reported a history of sexually transmitted diseases. Antibody to HSV-2 was detected in 39 .4%, but only 1.1% of seropositive women reported a history of genital herpes lesions. More than half the women had antibody to Chlamydia trachoma tis (56.1 %) and 6.4% had a reactive syphilis 1!\lHA-TP) serology. Women who had serologic evidence of past syphilis infection were almost twice as likely to !lave antibody to HSV -2 ns women nonreaCiive for syphilis r77.5% vs. 36.8%). Simiiariy, women with serological evidence of past chlamydia} infection were almost twice as likely to be seropositive for HSV -2 as women with no evidence of chlamyd:.. ial infections (50.3% vs. 25.9%). Of 44 women who had serological evidence of both syphilis and chlamydia! intection, 85.1% were seropositive for HSV-2; only 26.7n1J ofthe 313 women who were seronegative for both syphilis and chlamydia had serological evidence ofHSV-2 infection.
When analyzed by geographic region. the prevalence of HSV-2 antibody was highest (48.7%) in urban areas outside the central valley. chiefly the port cities of Limon and Puntarenas (data not shown). Education was inversely related to . seroprevalence ofHSV-2, even when controlled for age or for the number of lifetime sexual partners (Table 1 ). Previously married women had a seroprevalence almost twice as high as that of currently married women (62.3% vs. 35.2%).
The number of lifetime sexual partners was a strong predictor of seropositivity for HSV -2 for both older and younger women (Table 2) . Seroprevalence among women who reported only I sexual partner in their life was almost twice as high as the prevalence for the 36 women who denied having coitus (30.5% vs. 17. 7%}. Seraprevalence again doubled for women with 2 sexual partners compared to I partner (57.7% vs. 30.5%). Similarly, 61.6%ofwomen with 3 sexual partners during their life and 79.2% of women with 2:.4 partners were seropositive.
Seropositivity increased with age, even when controlled for the number otlifetime sexual partners (Table 1 ). However, in each age group, the prevalence of HSV -2 antibody among women with 2:.2 lifetime sexual partners was approximately twice as high as that of women with I or no partners.
Although women who reported a young age at first coitus had a higher seroprevalence, this difference diminished when controlled for the number of lifetime sexual partners (Table 2) . Seropositivity increased with the number of pregnancies, but this relationship wa.s pronounced only for women with ~2lifetime sexual partners. HSV-2 seroprevalence was not related to use of specific contraceptives, except for con- doms. Women whose partners had used con-than women whose partners had used condoms doms were less likely to have antibody to HSV -2 for <2 years. An apparent protective effect of than those whose partners had never used con-condom use also occurred when stratified by age doms (rable 3). Women whose partners had used or by the number oflifetime sexual partners (Tacondoms for ::::2 years had a lower prevalence ble 4). 
DISCUSSION
The high prevalence of specific HSV-2 antibody in Costa Rican women is consistent with the limited previous studies from Central America. One previous Costa Rican study reported that I 0 of20 selected clients in a family planning clinic had neutralizing antibody to HSV-2. 15 In Guatemala City, Guatemala. 45 of 60 selected outpatients were seropositive for HSV -2 as determined by an ELISA test (Juan Manual and Amaya Ferman, University of San Carlos, Guaterqala City, Guatemala, personal communication). A more specific serological text was used in Herrera Province, Panama. There, 33% of control subjects in a cervical cancer case~control study had HSV -2 antibody.' 6 None of these Panamanian women reported a history of genital herpes.
The seroprevalence of HSV-2 increased with age and varied by marital status and educational leveL However, the number of lifetime sexual partners demonstrated the most dramatic gradient for seropositivity. Two-fold differences in seroprevalence were observed between women with I sexual partner and women with no sexual experience and for women with 2 partners as compared to women with I sexual partner. Women with <::4lifetime sexual partners had a seropositivity of 79.2%, compared with 17.7% among women with no history of coitus. This latter group included only 6 seropositive wome~ and may have reflected perinatal infection, inaccurate sexual histories, oral transmission of HSV -2, or residual cross-reactivity with HSV -I.
Since most women in chis study (65.4%) reported only I sexual partner in their !ifr:, the seroprevalence estimate for the total population is primarily determined by the prevalence in this subgroup. Yet the seroprevalence among these monogamous women was high (30.5%). This strongly suggests that risk factors related to male sexual behavior, which were not measured in this study, are responsible for the high seroprevalence ofHSV-2 in Costa Rican women.
Very few women reported a history of genital herpes or any other sexually transmitted disease (STD). Some Costa Rican women may have been hesitant to report symptomatic genital herpes infection, or may not have been informed of the diagnosis by a clinician. But most genital herpes infections in Costa Rica are probably asymptomatic, as in other countries. 16 • 17 Women with serological evidence for syphilis or chlamydia! infection were twice as likely to have HSV -2 antibody than women with no serologic evidence for these diseases. These results suggest that women who had l STD were likely to have > 1. Condom use has been associated with a decreased risk for several sexually transmitted diseases. ' 8 In this study, the pattern of condom use (Tables 3, 4 ) is consistent with a protective effect against HSV-2. Women whose partners used condoms had a lower prevalence of HSV -2 antibody in both age groups as compared to nonusers. Among younger women and women with only I sexual partner, the long-term use of condoms(<:: 2 years) had a slightly lower HSV -2 seroprevalence than short-term users. However, since this is a prevalence rather than an incidence study, condom use could have occurred before or after HSV -2 infection.
The cross-sectional study design JL?O and the restriction to women 25-59 years of age impedes our ability to identify risk factors for HSV -2 infection.
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